Infliximab，注冊(cè)商標(biāo)為Remicade，中文名字為英利昔單抗、英夫利昔、因福利美、瑞米凱德、類(lèi)克。

英夫利昔單抗（Infliximab，Remicade）是一類(lèi)相對(duì)新型的生物制劑。為高親和性結(jié)合腫瘤壞死因子alpha (TNF-α)的嵌合體單抗，其被廣泛應(yīng)用于治療自身免疫性疾病。因此，檢測(cè)英夫利昔單抗、抗英夫利昔抗體血藥濃度及水平在治療和個(gè)性化用藥上具有重要意義。

Matriks Biotechnology專(zhuān)門(mén)生產(chǎn)針對(duì)抗體藥的ELISA試劑盒，用于檢測(cè)抗體藥的體內(nèi)濃度或因用該抗體藥產(chǎn)生的抗體的體內(nèi)濃度。Matriks Biotek®, SHIKARI®和KLONART®為Matriks Biotechnology注冊(cè)的產(chǎn)品商標(biāo)。其產(chǎn)品達(dá)到ISO 13485 & CE IVD標(biāo)準(zhǔn)。

英夫利昔(Infliximab， Remicade®) ELISA (Specific) 試劑盒

    英文名稱(chēng)：SHIKARI® QS-INFLIXI ELISA KIT； 貨號(hào)：TR-QS-INFLIXlv1； 規(guī)格：96T

英文描述：Enzyme immunoassay for the quantitative determination of Infliximab (Remicade®) in serum and plasma and other biological fluids

中文描述：ELISA方法特異性定量測(cè)定血清、血漿或其他生物液體中的英夫利昔單抗(Infliximab， Remicade®)的濃度

SHIKARI Q-INFLIXI ELISA KIT使用單克隆抗體高專(zhuān)一性結(jié)合血清、血漿或其他生物液中的英夫利昔單抗(Infliximab， Remicade®)，是當(dāng)前*一款用于定量檢測(cè)英夫利昔(Infliximab， Remicade®)體內(nèi)濃度的特異性ELISA試劑盒。

引用文獻(xiàn)：

#		PEER REVIEWED JOURNAL ARTICLES:
1		Gibellini L, De Biasi S, Bianchini E, et al. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis. Richard Y, ed. PLoS ONE. 11(12), 2016.**
4		Choi SY, Kang B, Lee JH, Choe YH. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut Liver. Sep 9 2016.**
6		Farkas K., et al., Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. Journal of Crohn's and Colitis Advance Access published April 21, 2016.
7		Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, Scharl M, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients with Crohn's Disease. Am J Gastroenterol. Apr;111(4):529-40, 2016.
8		Won Jae Song, Ben Kang, So Yoon Choi, and Yon Ho Choe. Adalimumab Treatment in Pediatric-Onset Crohn’s Disease Patients after Infliximab Failure: A Single Center Study. Pediatr Gastroenterol Hepatol Nutr. Jun; 19(2): 116–122, 2016.**
9		Hayashi S, et al., Early Prognostic Factors Associated with the Efficacy of Infliximab Treatment for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate. Rheumatol Ther (2016) 3:155–166 **
10		Bortlik M., et al., Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scandinavian Journal of Gastroenterology, 2016 vol. 51, no. 2, 196–202.
11		Al-Karkhi M.A., et al., Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital. IOSR Journal of Dental and Medical Sciences, Volume 14, Issue 11 Ver. IV (Nov. 2015), PP 95-100.**
14		Juanola O., et al., Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn’s disease. J Gastroenterol (2015) 50:758–768.
16		Malíckova K, et al., Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease, Biologicals 2015.
17		Farkas K. et al, Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis experiences from a single center. Expert Opin. Biol. Ther. 15:(9) 2015.
18		Lee Y.M. et al, Infliximab ‘‘Top-Down’’ Strategy is Superior to ‘‘Step-Up’’ in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. JPGN 60: (737–743), 2015.
19		Al-Karkhi M.A., et al., Development of Antibodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis. J Fac Med Baghdad, 57: (241-243), 2015.**
22		Pallagi-Kunstár É. et al., Utility of serum TNF-a, infliximab trough level, and antibody titers in inflammatory bowel disease. World J Gastroenterol. 20(17): (5031-5035), 2014. **
23		Khanna R., et al., Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology & Hepatology, August (478-489),2014. **
24		Krajcovicova A. et al., Delayed hypersensitivity reaction after initial dose of infliximab: a case report. European Journal of Gastroenterology& Hepatology 26:(485-487), 2014.
27		Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children. Inflamm Bowel Dis 20 : (495-451), 2014.
29		Gutierrez A, et al, Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn’s disease, Gut 0:1–9, 2013. **
30		Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease, J Crohns Colitis 2013. **
33		Bortlik M et al, “Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-a therapy during pregnancy: three-center study”, Scandinavian Journal of Gastroenterology. 48: 951–958, 2013
34		Bortlik M, et al, Infliximab trough levelsmay predict sustained response to infliximab in patients with Crohn's disease, Journal of Crohn's and Colitis 2012. **
35		Malickova K, et al, Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases, Autoimmun Highlights, 2012. **
36		Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology 2012; 39: 1- 4. **
37		Seok Lee Y, et al, “Efficacy of Early Infliximab Treatment for Pediatric Crohn’s Disease: A Three-year Follow-up”, Pediatric Gastroenterology, Hepatology & Nutrition 2012; 15(4):243-249 **
38		Molnar T, et al, “Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease”, Z Gastroenterol 2012; 50 - A53
39		Kato S, et al, “Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab Maintenance Therapy in a Crohn’s Disease Patient”, Crohn’s & Colitis Foundation of America 2011
40		Adisen E, et al, “Anti-infliximab antibody status and its relation to clinical response in psoriatic patients”: A pilot study, Journal of Dermatology 2010; 37: 708–713.

Matriks Biotechnology——抗體藥的藥效及個(gè)體化應(yīng)用專(zhuān)家

抗體藥是一類(lèi)相對(duì)新型的生物制劑。檢測(cè)抗體藥及其抗體水平在治療和個(gè)性化用藥上具有重要意義。大量的臨床和制藥公司都在致力于抗體藥物的濃度水平和療效的研究。Matriks生物技術(shù)公司專(zhuān)門(mén)生產(chǎn)針對(duì)抗體藥的ELISA試劑盒，用于檢測(cè)抗體藥的體內(nèi)含量或因用于產(chǎn)生的針對(duì)相應(yīng)抗體藥的抗體的體內(nèi)含量。Matriks Biotek?, SHIKARI?和KLONART?為Matriks生物技術(shù)公司注冊(cè)的產(chǎn)品商標(biāo)。其產(chǎn)品達(dá)到ISO 13485 & CE IVD標(biāo)準(zhǔn)。

Matriks生產(chǎn)用于檢測(cè)抗體藥在體內(nèi)的濃度和療效的試劑盒主要針對(duì)如下幾種抗體藥。

1. Infliximab注冊(cè)商標(biāo)為Remicade，由Schering-Plough生產(chǎn)，中文名字為英利昔單抗、英夫利昔、因福利美、瑞米凱德、類(lèi)克。

Infliximab為高親和性結(jié)合腫瘤壞死因子alpha (TNF-α)的嵌合體單抗，其被廣泛應(yīng)用于治療自身免疫性疾病。Matriks Biotek Shikari Infliximab ELISA使用單克隆抗體高專(zhuān)一性結(jié)合血清、血漿和其他生物液中的Infliximab，是當(dāng)前*的一款用于定量檢測(cè)Infliximab (Remicade?)體內(nèi)含量的特異性ELISA試劑盒。

2. Adalimumab注釋商標(biāo)為Humira, 為Abbott Laboratories產(chǎn)品，中文名阿達(dá)木單抗、修美樂(lè)。

Adalimumab為特異性結(jié)合TNF-α的人源性抗體，Adalimumab通過(guò)阻止TNF-α與其細(xì)胞表面受體相結(jié)合，發(fā)揮抗炎作用。

Matriks Biotek shikari抗體檢測(cè)抗Adalimumab抗體，用于檢測(cè)治療過(guò)程中抗Adalimumab抗體狀況，為醫(yī)師提供時(shí)機(jī)以減少抗Adalimumab抗體產(chǎn)生（例如添加免疫抑制性藥物），以阻止抗體藥失效。

3. Etanercept商標(biāo)為Enbrel和Altebrel，中文名依那西普，恩利.

是一種干擾TNF-α、用于自身免疫性疾病治療的生物藥物。針對(duì)Etanercept的特異性單抗用于檢測(cè)血樣中Etanercept量。Matriks Biotek Shikari Q-ETA是市面上用于定量檢測(cè)Etanercept的ELISA試劑盒。

4. 人腫瘤壞死因子及受體

Matriks Biotek開(kāi)發(fā)的高敏感度、專(zhuān)一性TNF-α檢測(cè)試劑盒，該試劑盒基于固定在固相面上的針對(duì)TNF-alpha的單抗和標(biāo)記了馬辣根過(guò)氧化物酶的另一單抗經(jīng)三明治夾心法檢測(cè)TNF-α。

5. Bevacizumab商標(biāo)名為Avastin?，由Genentech/Roche生產(chǎn)，中文名為阿瓦斯汀、貝伐單抗、安維汀、癌思停。

Bevacizumab為血管生成抑制劑，在包括結(jié)腸和直腸癌、肺癌、乳腺癌、腎癌、卵巢癌等多種腫瘤中被批準(zhǔn)使用。Matriks Biotek Shikari Q-BEVA Enzyme Immunoassay用于檢測(cè)血清或血漿中游離bevacizumab含量。以便保證其有效的血藥濃度。

6. Rituximab商標(biāo)為Rituxan, Mabthera, Zytux，中文名為利妥昔單抗注射劑、美羅華、利妥昔單抗、利克散、賀普丁、莫須瘤。

Rituximab為針對(duì)B細(xì)胞表面抗原CD20蛋白的嵌合型單克隆抗體。Rituximab可破壞B細(xì)胞，從而用于治療包括多種白血病、淋巴瘤、移植排斥和自身免疫失調(diào)性疾病等多種因B細(xì)胞過(guò)量、B細(xì)胞高反應(yīng)性和B細(xì)胞功能失調(diào)引起的疾病。Rituximab的使用可引起機(jī)體產(chǎn)生相應(yīng)抗體。Matriks Biotek Rituximab-ELISA和Rituximab抗體分別用于測(cè)定機(jī)體內(nèi)rituximab及其抗體的水平，從而為維持有效rituximab的血藥濃度和提供抗抗體措施提供預(yù)防性舉措。

7. Trastuzumab商標(biāo)名為Herclon, Herceptin，中文名為赫賽汀、賀癌平、曲妥珠單抗。

Trastuzumab為干擾HER2/neu受體的單克隆抗體，其主要用于乳腺癌的治療。Trastuzumab的使用可導(dǎo)致機(jī)體產(chǎn)生抗Trastuzumab抗體。Matriks Biotek Trastuzumab-ELISA和抗體分別用于檢測(cè)機(jī)體trastuzumab和其抗體的濃度。

Matriks Biotek抗體藥個(gè)性化用藥測(cè)試盒產(chǎn)品目錄

我們公司zui大優(yōu)勢(shì)是強(qiáng)大的采購(gòu)，

1：基本什么都能進(jìn)口，血清，抗體，耗材，還有部分限制進(jìn)口的，

2：貨品全，現(xiàn)經(jīng)營(yíng)過(guò)700多個(gè)品牌，基本所有生物試劑耗材都可以進(jìn)口，特別是冷偏的產(chǎn)品那就更有優(yōu)勢(shì)，

3：提供加急服務(wù)，一般1-2周到貨，超過(guò)時(shí)限加急費(fèi)全免

4：價(jià)格公道，絕大部分價(jià)格有優(yōu)勢(shì)，當(dāng)然不能保證100%產(chǎn)品都是,因?yàn)橐馕吨鴽](méi)有服務(wù).

5：良好的信譽(yù)，大部分客戶(hù)我們提供貨到付款服務(wù)，客戶(hù)包括清華，北大 交大 復(fù)旦，中山等100多所大學(xué)，ROCHE，阿斯利康，國(guó)藥 ，fisher等500多家公司

6：我們還是Santa,Advanced Biotechnologies Inc, Sorachim ,bangs,BBInternational,crystalchem,dianova,FD Neurotechnologies,Inc. Dako,Inc, GePromegaridege, Glycotope Biotechnology GmbH; iduron,Innovative Research of America, Ludger, neuroprobe,Sorachim , Polysciences,prospecbi, QA-BIO,quickzyme,FULLERLABS,INC,sterlitech；sysy,TriLink BioTechnologies,Inc；worthington-biochem,zyagen等幾十家國(guó)外公司授權(quán)代理。
7：我們還是invitrogen,qiagen,Sorachim am,sigma;Promega,roche,merck, rnd,BD, GE,pierce,BioLegend等*批發(fā)，歡迎合作。

上海起發(fā)實(shí)驗(yàn)試劑有限公司
：楊建輝
400：
辦公：
*8006

企業(yè):
:http://www.qfbio。。ｃｏｍ/
地址：上海市浦東新區(qū)晨陽(yáng)路225弄東方現(xiàn)代商業(yè)廣場(chǎng)46號(hào)303室(近東亭路)